Literature DB >> 21135277

Taming glioblastoma by targeting angiogenesis: 3 years later.

Eric T Wong, Steven Brem.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21135277     DOI: 10.1200/JCO.2010.32.5282

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  7 in total

Review 1.  Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors.

Authors:  Terri S Armstrong; Patrick Y Wen; Mark R Gilbert; David Schiff
Journal:  Neuro Oncol       Date:  2012-02-03       Impact factor: 12.300

Review 2.  Normalization of the vasculature for treatment of cancer and other diseases.

Authors:  Shom Goel; Dan G Duda; Lei Xu; Lance L Munn; Yves Boucher; Dai Fukumura; Rakesh K Jain
Journal:  Physiol Rev       Date:  2011-07       Impact factor: 37.312

Review 3.  Activation of alternative pathways of angiogenesis and involvement of stem cells following anti-angiogenesis treatment in glioma.

Authors:  Ali S Arbab
Journal:  Histol Histopathol       Date:  2012-05       Impact factor: 2.303

4.  Vascular mimicry in glioblastoma following anti-angiogenic and anti-20-HETE therapies.

Authors:  Kartik Angara; Mohammad H Rashid; Adarsh Shankar; Roxan Ara; Asm Iskander; Thaiz F Borin; Meenu Jain; Bhagelu R Achyut; Ali S Arbab
Journal:  Histol Histopathol       Date:  2016-12-19       Impact factor: 2.303

Review 5.  State of the art and perspectives in the treatment of glioblastoma.

Authors:  Sean A Grimm; Marc C Chamberlain
Journal:  CNS Oncol       Date:  2012-09

6.  Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues.

Authors:  Yunlong Yang; Yin Zhang; Ziquan Cao; Hong Ji; Xiaojuan Yang; Hideki Iwamoto; Eric Wahlberg; Toste Länne; Baocun Sun; Yihai Cao
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-01       Impact factor: 11.205

7.  Antiangiogenic therapy for patients with recurrent and newly diagnosed malignant gliomas.

Authors:  Katsuyuki Shirai; Michael R Siedow; Arnab Chakravarti
Journal:  J Oncol       Date:  2011-07-14       Impact factor: 4.375

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.